Patients with septicemia or severe infectionXx_NEWLINE_xXPatients with septicemia or severe infectionXx_NEWLINE_xXActive systemic infection or skin infection at or near the acupuncture sitesXx_NEWLINE_xXPROCUREMENT: Patients with severe intercurrent infectionXx_NEWLINE_xXTREATMENT: Patients with severe intercurrent infectionXx_NEWLINE_xXA second malignancy requiring active therapyXx_NEWLINE_xXPatients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapyXx_NEWLINE_xXPatients should not have any evidence of active or uncontrolled infection requiring treatment with antibioticsXx_NEWLINE_xXPatients should not have any clinical evidence of an active infection at the time of enrollmentXx_NEWLINE_xXPatients with a previous or current line infection are ineligible until 14 days after the completion of antibioticsXx_NEWLINE_xXClinically active infection; an active infection may alter the biodistribution of 18F-FLTXx_NEWLINE_xXActive bacterial or fungal infection; all prior infections must be resolved following optimal therapyXx_NEWLINE_xXAcute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 14 days prior to randomizationXx_NEWLINE_xXPatients must not have any incidence of or uncontrolled medical illness (e.g. active cardiac symptoms, active systemic infection, etc.) that would limit the patient�s ability to participate in the protocolXx_NEWLINE_xXUncontrolled intercurrent illness including active infectionXx_NEWLINE_xXAcute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 2 weeks before Segment B enrollmentXx_NEWLINE_xXActive lung infectionXx_NEWLINE_xXConcurrent, acute, active infection, or treatment for infection, other than oral thrush or genital herpes, within 14 days of enrollmentXx_NEWLINE_xXActive infection or chronic infection requiring chronic suppressive antibioticsXx_NEWLINE_xXInfection requiring systemic antibiotic therapy or other serious infection within 14 days before registrationXx_NEWLINE_xXOpportunistic infection within the last 3 monthsXx_NEWLINE_xXOngoing or active infection; treatment with systemic antibiotics or antifungals for ongoing or recurrent infection (topical use of antibiotics or antifungals is allowed)Xx_NEWLINE_xXSymptomatic/active bacterial, or fungal, or any other opportunistic infectionXx_NEWLINE_xXPatients must not have any incidence of or uncontrolled medical illness (e.g. active cardiac symptoms, active systemic infection, etc.) that would limit the patient�s ability to participate in the protocolXx_NEWLINE_xXActive infectionXx_NEWLINE_xXActive or chronic infection requiring systemic therapyXx_NEWLINE_xXPatients must not have a serious intercurrent illness, including ongoing or active infection requiring parental antibioticsXx_NEWLINE_xXPatients must not have an active infection requiring systemic therapyXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.Xx_NEWLINE_xXPatients must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligibleXx_NEWLINE_xXSevere and/or symptomatic refractory concurrent infection other than EBVXx_NEWLINE_xXPatients who have an active uncontrolled infection defined as: * Positive bacterial blood culture within 48 hours of study enrollment; * Fever above 38.2 degree Celsius (C) within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability* A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection* Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved; for patients with clostridium (c.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline* Active viral or protozoal infection requiring IV treatmentXx_NEWLINE_xXActive, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilationXx_NEWLINE_xXPatients must not have an active infection requiring systemic therapyXx_NEWLINE_xXPatients must not have an active infection requiring systemic therapy nor a viral infection requiring intermittent treatment with an antiherpetic drug, other than intermittent topical useXx_NEWLINE_xXPatients must not have an active infection requiring systemic therapy at time of registrationXx_NEWLINE_xX